Cargando…
Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury
PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite rece...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329699/ https://www.ncbi.nlm.nih.gov/pubmed/25709764 http://dx.doi.org/10.4103/2008-322X.150803 |
_version_ | 1782357477479677952 |
---|---|
author | Jadidi, Khosrow Panahi, Yunes Ebrahimi, Ali Mafi, Mostafa Nejat, Farhad Sahebkar, Amirhossein |
author_facet | Jadidi, Khosrow Panahi, Yunes Ebrahimi, Ali Mafi, Mostafa Nejat, Farhad Sahebkar, Amirhossein |
author_sort | Jadidi, Khosrow |
collection | PubMed |
description | PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite receiving artificial tears and punctal plugs. Patients were administered tCsA 0.05% twice daily for 3 months. Severity of the condition was evaluated by measuring tear osmolarity, ocular surface disease index (OSDI), tear break-up time (TBUT), and Schirmer's test at baseline and at the end of study. RESULTS: A total of 34 patients with chronic MG injury and mean age of 47.1 ± 6.5 years were studied. Compared to baseline values, tear osmolarity (301.7 ± 11.5 vs. 286.3 ± 7.9 mOsmol/L, P < 0.001) and OSDI (47.5 ± 7.2 vs. 42.7 ± 7.1, P < 0.001) were significantly improved. Likewise, Schirmer's test (4.6 ± 1.3 vs. 5 ± 1.3 mm, P < 0.001) and TBUT (1.9 ± 1.4 vs. 2.7 ± 1.5 s, P < 0.001) also significantly recovered at the end of the study. CONCLUSION: TCsA 0.05% reduces tear osmolarity and improves dry eye symptoms and can serve as an efficacious treatment for ocular complications in patients with chronic MG injury. |
format | Online Article Text |
id | pubmed-4329699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43296992015-02-23 Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury Jadidi, Khosrow Panahi, Yunes Ebrahimi, Ali Mafi, Mostafa Nejat, Farhad Sahebkar, Amirhossein J Ophthalmic Vis Res Original Article PURPOSE: To evaluate the efficacy of topical cyclosporine A (tCsA) for treatment of dry eye disease in patients suffering from chronic ocular complications of mustard gas (MG) injury. METHODS: This interventional case series included patients with MG injury suffering from severe dry eye despite receiving artificial tears and punctal plugs. Patients were administered tCsA 0.05% twice daily for 3 months. Severity of the condition was evaluated by measuring tear osmolarity, ocular surface disease index (OSDI), tear break-up time (TBUT), and Schirmer's test at baseline and at the end of study. RESULTS: A total of 34 patients with chronic MG injury and mean age of 47.1 ± 6.5 years were studied. Compared to baseline values, tear osmolarity (301.7 ± 11.5 vs. 286.3 ± 7.9 mOsmol/L, P < 0.001) and OSDI (47.5 ± 7.2 vs. 42.7 ± 7.1, P < 0.001) were significantly improved. Likewise, Schirmer's test (4.6 ± 1.3 vs. 5 ± 1.3 mm, P < 0.001) and TBUT (1.9 ± 1.4 vs. 2.7 ± 1.5 s, P < 0.001) also significantly recovered at the end of the study. CONCLUSION: TCsA 0.05% reduces tear osmolarity and improves dry eye symptoms and can serve as an efficacious treatment for ocular complications in patients with chronic MG injury. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4329699/ /pubmed/25709764 http://dx.doi.org/10.4103/2008-322X.150803 Text en Copyright: © Journal of Ophthalmic and Vision Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jadidi, Khosrow Panahi, Yunes Ebrahimi, Ali Mafi, Mostafa Nejat, Farhad Sahebkar, Amirhossein Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury |
title | Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury |
title_full | Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury |
title_fullStr | Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury |
title_full_unstemmed | Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury |
title_short | Topical Cyclosporine A for Treatment of Dry Eye Due to Chronic Mustard Gas Injury |
title_sort | topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329699/ https://www.ncbi.nlm.nih.gov/pubmed/25709764 http://dx.doi.org/10.4103/2008-322X.150803 |
work_keys_str_mv | AT jadidikhosrow topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury AT panahiyunes topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury AT ebrahimiali topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury AT mafimostafa topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury AT nejatfarhad topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury AT sahebkaramirhossein topicalcyclosporineafortreatmentofdryeyeduetochronicmustardgasinjury |